Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture

F Grillet; E Bayet; O Villeronce; L Zappia; EL Lagerqvist; S Lunke; E Charafe-Jauffret; K Pham; C Molck; N Rolland; JF Bourgaux; M Prudhomme; C Philippe; S Bravo; JC Boyer; L Canterel-Thouennon; GR Taylor; A Hsu; JM Pascussi; F Hollande; J Pannequin

Journal article

Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture

F Grillet, E Bayet, O Villeronce, L Zappia, EL Lagerqvist, S Lunke, E Charafe-Jauffret, K Pham, C Molck, N Rolland, JF Bourgaux, M Prudhomme, C Philippe, S Bravo, JC Boyer, L Canterel-Thouennon, GR Taylor, A Hsu, JM Pascussi, F Hollande Show all

Gut | BMJ PUBLISHING GROUP | Published : 2017

DOI: 10.1136/gutjnl-2016-311447

Download PDF

Abstract

Objective Although counting of circulating tumour cells (CTC) has attracted a broad interest as potential markers of tumour progression and treatment response, the lack of functional characterisation of these cells had become a bottleneck in taking these observations to the clinic. Our objective was to culture these cells in order to understand them and exploit their therapeutic potential to the full. Design Here, hypothesising that some CTC potentially have cancer stem cell (CSC) phenotype, we generated several CTC lines from the blood of patients with advanced metastatic colorectal cancer (CRC) based on their self-renewal abilities. Multiple standard tests were then employed to characteris..

View full abstract

University of Melbourne Researchers

Sebastian Lunke Author

Frederic Hollande Author

Related Projects (3)

Elucidating the role of claudin-2 in tumour initiation and metastasis development from colorectal cancer: consequence for tumour relapse

Mortality from colorectal cancer is often due to the development of metastases. Cancer stem cells (CSC) are suspected to provide a major dri..

ESTABLISHING AND VALIDATING A NEW THERPAUETIC TARGET FOR COLON AND STOMACH CANCER

Cancers of the stomach and the colon are a major health burden. One of the central signaling molecules that drives these cancers is called S..

TARGETING COLON CANCER WITH JAK INHIBITORS

Colorectal cancer (CRC) is the 3rd most common cancer worldwide. 85% of CRC arises from mutations in the Wnt signalling pathway. We have sho..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

Universite Montpellier I (BQR to FH), La ligue contre le cancer (to JP and FG), FH is supported by The University of Melbourne Department of Pathology and by the National Health and Medical Research Council (NHMRC) of Australia (grants #1049561, 1064987, 1069024). SIRIC: Grant "INCa-DGOS-Inserm 6045".